HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 03, March 2019 – Driven by curiosity — Exclusive interview with Nobel laureate Ada Yonath: Her journey in science wasn't always crystal clear       » Your eyes don't deceive you, your brain does       » Organ donations to be computerised in China       » Over One tenth of Chinese people have mental health problems       » AI system can diagnose childhood diseases like doctors       » Bitter rapeseed potential protein source for human nutrition      
BIOBOARD: ASIA-PACIFIC
New use of anti-parasitic drug to potentially treat cancer
Unprecedented use of niclosamide, an FDA-approved anti-parasitic drug, to kill p53-defective cancer cells

Clinicians and scientists from Singapore have discovered the unprecedented use of an FDA-approved drug to kill p53-defective cancer cells.

The discovery was made by a research team led by scientists from A*STAR’s Institute of Molecular and Cell Biology (IMCB), and the findings were published in Nature Communications.

They discovered that niclosamide, an FDA-approved anti-parasitic drug, can effectively kill p53-defective cancer cells, potentially increasing the specificity for cancer targeting and sparing normal cells that carry wildtype p53 (the p53 gene in its natural or non-mutated form).

Mutations of the p53 gene in the human body is the one of the most common occurrences found in cancer cells and is present in over 50 percent of cancers. The p53 gene is a tumour suppressor gene that inhibits the growth of tumours, and if this gene is mutated, cancer cells are able to thrive.

niclosamide, a drug conventionally used in the treatment of intestinal tapeworm infections, was found to induce metabolic stress in colon cancer cells without p53, effectively causing death of these cancer cells. This discovery supports the potential use of niclosamide as a first-in-class drug against a broad spectrum of tumours deficient in p53 functions.

“The advantage of repurposing an FDA-approved drug for novel indications is the quicker time-to-market since information on their pharmacology and potential toxicity is already available. This can help to reduce cost and time in developing new candidate therapies and speed up the pipeline of available therapeutics redirected for targeting cancers,” said Dr Chit Fang Cheok, principal investigator at A*STAR’s IMCB and lead researcher of the study.

Moving forward, the research team plans to test the efficacy of niclosamide against a broader cohort of tumour types from potential cancers such as breast, lung and liver.

Click here for the complete issue.

NEWS CRUNCH  
news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy